FRESENIUS SE+CO. ADR 1/4 (FREA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FRESENIUS SE+CO. ADR 1/4 (FREA) has a cash flow conversion efficiency ratio of 0.068x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.34 Billion ≈ $1.57 Billion USD) by net assets (€19.77 Billion ≈ $23.11 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FREA company net worth for the company's overall valuation and market capitalisation.
FRESENIUS SE+CO. ADR 1/4 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how FRESENIUS SE+CO. ADR 1/4's cash flow conversion efficiency has evolved over time, based on yearly financial data.
FRESENIUS SE+CO. ADR 1/4 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FRESENIUS SE+CO. ADR 1/4 ranked by their cash flow conversion efficiency. Explore earnings quality score of FRESENIUS SE+CO. ADR 1/4 to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Quantum Minerals Ltd
TO:FM
|
0.011x |
|
Sungrow Power Supply Co Ltd
SHE:300274
|
0.128x |
|
Dollar General Corporation
NYSE:DG
|
0.081x |
|
Insmed Inc
NASDAQ:INSM
|
-0.232x |
|
Huntington Bancshares Incorporated
NASDAQ:HBAN
|
0.022x |
|
China National Nuclear Power
SHG:601985
|
0.057x |
|
Ecopetrol SA ADR
NYSE:EC
|
0.050x |
|
American Water Works
NYSE:AWK
|
0.052x |
Annual Cash Flow Conversion Efficiency for FRESENIUS SE+CO. ADR 1/4 (2021–2025)
The table below shows the annual cash flow conversion efficiency of FRESENIUS SE+CO. ADR 1/4 from 2021 to 2025. View today's stock price for FRESENIUS SE+CO. ADR 1/4 for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.77 Billion ≈ $23.11 Billion |
€2.57 Billion ≈ $3.01 Billion |
0.130x | +7.97% |
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.121x | -46.81% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
€4.46 Billion ≈ $5.21 Billion |
0.227x | +74.03% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.130x | -24.85% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
€5.08 Billion ≈ $5.94 Billion |
0.173x | -- |
About FRESENIUS SE+CO. ADR 1/4
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more